natgillin/translations-raw huggingface dataset:
intravenous 2 hr
intravensko 2 h
intravenous 22 hr
intravensko 22 h
Intravenous abatacept has been studied in patients with active rheumatoid arthritis in placebo- controlled clinical trials (2,111 patients with abatacept, 1,099 with placebo).
Intravensko uporabo abatacepta so raziskovali pri bolnikih z aktivnim revmatoidnim artritisom v s placebom nadzorovanih kliničnih preskušanjih (2.111 bolnikov je prejemalo abatacept, 1.099 placebo).
Intravenous administration (first dose in patients with STEMI only)
Intravenska uporaba (le prvi odmerek pri bolnikih s STEMI)
Intravenous administration as two consecutive infusions over 5 to 10 min each or as bolus injections
Zdravilo Praxbind dajemo intravensko v dveh zaporednih infuzijah, ki vsaka traja 5 do 10 minut, ali kot bolusno injekcijo.
Intravenous administration occurs preferably through a running intravenous infusion over 20-30 minutes (see section 6.6).
Po možnosti je treba zdravilo aplicirati v obliki 20-30-minutne intravenske infuzije (glejte poglavje 6.6).
Intravenous administration of 14C-labelled isavuconazonium sulfate to lactating rats resulted in the recovery of radiolabel in the milk.
Po intravenskem dajanju izavukonazonijevega sulfata, označenega s 14C, doječim podganam, je bilo radioaktivno označeno spojino mogoče najti v mleku.
Intravenous administration of bivalirudin produces measurable anticoagulation within minutes.
Intravensko dajanje bivalirudina v nekaj minutah povzroči merljivo antikoagulacijo.
Intravenous administration of Cerenia should be given as a single bolus without mixing the product with any other fluids.
Zdravilo Cerenia je ob intravenskem dajanju treba dati kot enkratni bolusni odmerek brez mešanja zdravila s katero koli drugo tekočino.
Intravenous administration of hydrocortisone is warranted during transient illness episodes such as severe infections, in particular gastroenteritis associated with vomiting and/or diarrhoea, high fever of any aetiology or extensive physical stress, such as for instance serious accidents and surgery under general anaesthesia, see section 4.4.
Intravenska uporaba hidrokortizona je nujno potrebna med prehodnimi epizodami bolezni, kot so hude okužbe, zlasti gastroenteritis, povezan z bruhanjem in/ali drisko, in močno zvišana telesna temperatura katerekoli etiologije ter pri velikem telesnem naporu, kot so hude nesreče ali operacije pod splošno anestezijo, glejte poglavje 4.4.
Intravenous administration of insulin:
Intravensko dajanje insulina:
Intravenous administration through a central venous line is strongly recommended (see sections 4.4 and 6.6).
Močno se priporoča intravensko dajanje zdravila skozi centralno vensko linijo (glejte poglavji 4.4 in 6.6).
Intravenous administration was associated with local side effects such as :
Lokalni neželeni učinki, ki so povezani z intravensko uporabo so:
Intravenous and
Intravenska in
Intravenous and subcutaneous administration to monkeys resulted in the expected depletion of peripheral and lymphoid tissue B cell counts with no associated toxicological findings.
Intravenska oziroma subkutana uporaba je pri opicah povzročila pričakovano zmanjšanje števila perifernih celic B in celic B v limfatičnem tkivu, brez spremljajočih toksikoloških ugotovitev.
Intravenous aztreonam is not suitable for inhalation.
Aztreonam za intravensko uporabo ni primeren za vdihavanje in ni bil dovoljen za inhaliranje.
intravenous bag or
infuzijsko vrečko ali
intravenous bolus,
intravensko bolus,
Intravenous bolus: brivaracetam may be administered as an intravenous bolus without dilution.
Intravenski bolus: brivaracetam lahko dajete kot intravenski bolus brez razredčenja.
intravenous corticosteroid (methylprednisolone 100 mg, or equivalent dose of an intermediate-acting or long-acting corticosteroid) plus
intravenski kortikosteroid (metilprednizolon 100 mg ali enakovreden odmerek drugega srednje dolgo delujočega ali dolgo delujočega kortikosteroida) in
Intravenous corticosteroid1 (mandatory)
Intravenski kortikosteroid1 (obvezno)
Intravenous corticosteroid1 (recommended)
Intravenski kortikosteroid1 (priporočljivo)
Intravenous daptomycin doses of 5 to 10 mg/kg were administered and 256 children received daptomycin, from which pharmacokinetic sampling was performed on 45 children from across the age groups.
256 otrok je prejemalo daptomicin z intravensko infuzijo v odmerkih od 5 do 10 mg/kg in izmed teh so 45 otrokom iz vseh starostnih skupin jemali vzorce krvi za farmakokinetične meritve.
intravenous docetaxel - 100 mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 4 cycles (day 2 of first docetaxel cycle, then day 1 of each subsequent cycle)
docetaksel intravensko – 100 mg/m2 v obliki intravenske infuzije v 1 uri, vsake 3 tedne, skupaj 4 cikle (na 2. dan prvega cikla, potem pa na 1. dan vsakega nadaljnjega cikla)
intravenous drug users,
intravenskih drog, okuženih z
intravenous drug users,
pri bolnikih, ki so prejemali
intravenous erythromycin (an antibiotic)
eritromicin v žilo (antibiotik)
intravenous infusion
traja do 45 ur
Intravenous infusion (over 10 minutes) or by oral administration
intravenska infuzija (10-minutna) ali peroralno dajanje
Intravenous infusion (over 30 minutes)
intravenska infuzija (30-minutna)
Intravenous infusion administration
Intravensko infundiranje
Intravenous infusion administration:
Intravensko infundiranje
Intravenous infusion after reconstitution and dilution.
intravensko infundiranje po rekonstituciji in redčenju
Intravenous infusion of 52 mg/m2 clofarabine produced equivalent exposure across a wide range of weights.
Pri intravenskem infundiranju 52 mg klofarabina/m2 je bila izpostavljenost pri bolnikih z zelo različno telesno maso enaka.
Intravenous infusion of Oncaspar is usually given over a period of 1 to 2 hours in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution together with an already-running infusion.
Intravensko infuzijo zdravila Oncaspar običajno dajemo v obdobju 1 do 2 ur v 100 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje ali 5 % raztopino glukoze, skupaj z infuzijo, ki je že v uporabi.
Intravenous infusion over 3 hours (see section 6.6).
3-urno intravensko infundiranje (glejte poglavje 6.6).
Intravenous infusion: brivaracetam may be diluted in a compatible diluent and administered as a 15-minute intravenous infusion (see section 6.6).
Intravenska infuzija: brivaracetam lahko razredčite s kompatibilnim topilom in dajete kot 15- minutno intravensko infuzijo (glejte poglavje 6.6).
Intravenous infusions of cetuximab exhibited dose-dependent pharmacokinetics at weekly doses ranging from 5 to 500 mg/m2 body surface area.
Pri intravenskem infundiranju cetuksimaba so ugotavljali od odmerka odvisno farmakokinetiko s tedenskimi odmerki od 5 do 500 mg/m² telesne površine.
Intravenous injection technique (for acute STEMI indication only)
Metoda intravenskega (bolusnega) injiciranja (samo za indikacijo akutnega STEMI)
Intravenous Mepolizumab
mepolizumab intravensko
Intravenous mepolizumab pharmacokinetics was evaluated by population pharmacokinetic analysis in a paediatric study conducted in subjects aged 2–17 years old with eosinophilic esophagitis.
Farmakokinetiko intravensko uporabljenega mepolizumaba so ocenili s populacijsko farmakokinetično analizo v pediatrični študiji bolnikov z eozinofilnim ezofagitisom, starih od 2 do 17 let.
Intravenous mycophenolate mofetil should be administered for the first 4°days following hepatic transplant, with oral Mycophenolate mofetil Teva initiated as soon after this as it can be tolerated.
Prve 4 dni po presaditvi jeter je treba dajati mofetilmikofenolat intravensko, takoj ko je bolnik sposoben požirati, pa nadaljujemo s peroralno obliko zdravila Mofetilmikofenolat Teva.
Intravenous or intramuscular use
za intravensko ali intramuskularno uporabo
Intravenous or subcutaneous
Intravensko ali subkutano dajanje
Intravenous or subcutaneous use.
Za intravensko ali subkutano uporabo.
intravenous paclitaxel - 80 mg/m2 as a continuous intravenous infusion, given every week for 12 weeks.
paklitaksel intravensko – 80 mg/m2 v obliki kontinuirane intravenske infuzije, vsak teden, skupaj 12 tednov
intravenous push doxorubicin, at 60 mg/ m2, given every 3 weeks for 4 cycles. intravenous cyclophosphamide, at 600 mg/ m2 over 30 minutes, given every 3 weeks for 4 cycles.
doksorubicin v obliki intravenskega bolusa – 60 mg/m2, vsake 3 tedne, 4 cikle; ciklofosfamid intravensko – 600 mg/m2 v 30 minutah, vsake 3 tedne, 4 cikle.
Intravenous reconstitution:
Intravenska rekonstitucija:
Intravenous rhythm control AADs should not be used in the first 4 hours after BRINAVESS administration.
Intravenskih antiaritmikov za kontrolo srčnega ritma se v prvih 4 urah po uporabi zdravila BRINAVESS ne sme uporabljati.
Intravenous sodium chloride 9 mg/mL (0.9%) solution for injection (10 mL/kg) should be administered over one hour just prior to the dinutuximab infusion.
Tik pred infuzijo dinutuksimaba je treba dati injekcijo (10 ml/kg) natrijevega klorida 9 mg/ml (0,9 %) raztopine za injiciranje za eno uro.
Intravenous therapy using the initial bolus injection of atosiban 6.75 mg/0.9 ml, solution for injection (see Summary of Product Characteristics of this product) should be started as soon as possible after diagnosis of pre-term labour.
Intravensko zdravljenje z začetno bolusno injekcijo zdravila atosibana 6,75 mg/0,9 ml raztopina za injiciranje (glejte povzetek glavnih značilnosti zdravila za to zdravilo) je treba začeti čim prej po diagnozi prezgodnjega poroda.
Intravenous unfractionated heparin (UFH):
Intravenski nefrakcionirani heparin (INH):
Intravenous use
(steklo);vehikel:
Intravenous use
intarvenska uporaba
Intravenous use
Intravenozna uporaba
intravenous use
intravenozno
Intravenous use
intravensk
Intravenous use
intravenska
Intravenous use
intravenska aplikacija
Intravenous use
Intravenski uporaba
Intravenous use
Intravenski uporaba Intravenski uporaba
Intravenous use
Intravensko
intravenous use
intravensko uporabo
intravenous use
Pot uporabe zdravila
Intravenous use
ubkutana ali intravenska uporaba
intravenous use
uporaba
Intravenous use
uporaba Intravenska
intravenous use
Za intravensko in subkutano uporabo
Intravenous use (cattle and horses), subcutaneous use (cattle)
intravenska uporaba (goveda in konji); subkutana uporaba (goveda)
Intravenous use (dogs), Intramuscular use (dogs and cats)
Intravenska uporaba (psi), Intramuskularna uporaba (psi, mačke)
Intravenous use (IV)
intravenska uporaba (i.v.).
Intravenous use after dilution.
Po redčenju intravenska uporaba.
Intravenous use after reconstitution and dilution
Intravenska uporaba po rekonstituciji in redčenju
Intravenous use after reconstitution and dilution
Za intravensko uporabo po pripravi in redčenju.
Intravenous use after reconstitution and dilution Read the package leaflet before use
intravenska uporaba po rekonstituciji in redčenju Pred uporabo preberite priloženo navodilo
Intravenous use by infusion.
intravenska uporaba v obliki infuzije
Intravenous use Clinical efficacy
Intravenska uporaba Klinična učinkovitost
intravenous use Subcutaneous or intravenous use Subcutaneous use
Subkutana ali intravenska uporaba
intravenous use Subcutaneous or intravenous use Subcutaneous use
ubkutana ali intravenska uporaba
intravenous use Subcutaneous use
ubkutana uporaba
Intravenous use,
intravenska
Intravenous use, after dilution.
Za intravensko uporabo po rekonstituciji.
Intravenous use, for infusion after dilution Read the package leaflet before use
Za intravensko uporabo, za infuzijo po razredčitvi Pred uporabo preberite priloženo navodilo
Intravenous use, single use only
Intravenska uporaba, samo za enkratno uporabo.
Intravenous use, Subcutaneous use
intravenska
Intravenous use, Subcutaneous use
intravenska uporaba
Intravenous use, subcutaneous use
intravenska uporaba, subkutana uporaba
Intravenous use, Subcutaneous use
Subkutana ali
Intravenous use, Subcutaneous use
uporaba, subkutana uporaba intravenska
Intravenous used after reconstitution and dilution
Za intravensko uporabo po rekonstituciji in redčenju.
Intravenous used after reconstitution and dilution
Za intravensko uporabo po rekosnstituciji in redčenju.
Intravenous:
Pri intravenskem vnosu
Intravenously 0.3 mg/kg bw of enoxaparin if the last dose was administered subcutaneously over 8 hours before filling the balloon.
0,3 mg/kg TM enoksaparina intravensko, če je bil zadnji subkutani odmerek uporabljen več kot 8 ur pred balonskim širjenjem.
Intravenously administered midazolam (1 mg single dose)/ Tenofovir alafenamide (25 mg once daily)
Intravenski midazolam (1 mg enkratni odmerek)/alafenamidtenofovirat (25 mg enkrat dnevno)
Intravenously administered midazolam (once daily), tenofovir alafenamide (25 mg once daily)
intravenski midazolam (enkrat dnevno), alafenamidtenofovirat (25 mg enkrat dnevno)
Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½  0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Intravensko uporabljena zoledronska kislina se odstranjuje iz telesa v treh fazah: najprej se pojavi hitro dvofazno izginotje iz sistemskega obtoka z razpolovnima časoma t½  0,24 ure in t½β 1,87 ure, ki mu sledi dolga eliminacijska faza s terminalnim eliminacijskim razpolovnim časom t½γ 146 ur.
Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Intravensko dana zoledronska kislina se odstranjuje iz telesa s trifaznim procesom: hitro dvofazno izginotje iz sistemskega krvnega obtoka z razpolovnima časoma t½α 0,24 in t½β 1,87 ur, ki mu sledi dolga eliminacijska faza s terminalnim eliminacijskim razpolovnim časom t½γ 146 ur.
Intravitreal implant in applicator
Intravitrealni vsadek v aplikatorju
Intravitreal injection procedure pictogram
Slikovno navodilo (piktogram) s prikazom postopka intravitrealnega injiciranja
Intravitreal injection procedure video
video postopek intravitrealnega injiciranja
Intravitreal injection procedure video
Video s prikazom postopka intravitrealnega injiciranja
Intravitreal injection procedure video
videoposnetek postopka intravitrealnega injiciranja
Intravitreal use.
intravitrealna uporaba
Intrinsa 300 micrograms/24 hours transdermal patch
Intrinsa 300 mikrogramov/24 ur transdermalni obliž
Intrinsa is a thin, clear, oval patch with T001 stamped on the back.
Intrinsa je tanek, prozoren, ovalen obliž z napisom T001, natisnjenim na zadnji strani.
Intrinsa is intended for use by women up to the age of 60 years who:
Zdravilo Intrinsa je namenjeno ženskam, starim do 60 let, ki:
Intrinsa is not for use in children and adolescents.
Zdravilo Intrinsa ni namenjeno uporabi pri otrocih in mladostnikih.
Intrinsa is not recommended in naturally menopausal women.
Uporaba zdravila Intrinsa se ne priporoča ženskam po naravni menopavzi.
Intrinsa must not be used by breast-feeding women.
Doječe ženske ne smejo uporabljati zdravila Intrinsa.
Intrinsa must not be used in women who are or may become pregnant.
Zdravila Intrinsa ne smejo uporabljati nosečnice ali ženske, ki lahko zanosijo.
Intrinsa should not be used in naturally menopausal women
Zdravila Intrinsa se ne sme uporabljati pri ženskah po naravni menopavzi
Intrinsa should not be used in women on concomitant CEE
Zdravila Intrinsa se ne sme uporabljati pri ženskah, ki sočasno uporabljajo CEE
Intrinsa treatment response should be evaluated within 3-6 months of initiation, to determine if continued therapy is appropriate.
Odziv na zdravljenje z zdravilom Intrinsa je treba oceniti v 3–6 mesecih po začetku zdravljenja, da bi določili, ali je nadaljevanje zdravljenja primerno.
Intrinsic factors affecting ponatinib pharmacokinetics
Intrinzični dejavniki, ki vplivajo na farmakokinetiko ponatiniba
Introduce the atraumatic cannula in the ear canal.
Uvedite atravmatsko kanilo v ušesni kanal.
Introduce the solvent into the chromatography tank to a depth of approximately 2 cm.
Prenesite topilo v kromatografsko kopel do višine približno 2 cm.
Introduction to the product: provide information on the contents of the box ie that 28 days treatment is 56 capsules and 1 device.
Predstavitev zdravila: podatki o vsebini škatle, tj. da je za 28-dnevno zdravljenje v škatli 56 kapsul in 1 pripomoček.
IntronA 10 million IU/mL solution for injection or infusion interferon alfa-2b
IntronA 10 milijonov i.e./ml raztopina za injiciranje ali infundiranje interferon alfa-2b
IntronA 10 MIU solution
IntronA 10 mio i.e. raztopina
IntronA 18 million IU solution for injection in multidose pen
IntronA 18 milijonov i.e., raztopina za injiciranje, večodmerni peresnik
IntronA 18 million IU solution for injection in multidose pen interferon alfa-2b
IntronA 18 milijonov i.e. raztopina za injiciranje v večodmernem peresniku interferon alfa-2b
IntronA 18 million IU/3 mL solution for injection or infusion interferon alfa-2b
IntronA 18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje interferon alfa-2b
IntronA 18 MIU pen
IntronA 18 mio i.e. peresnik
IntronA 18 MIU solution
IntronA 18 mio i.e. raztopina
IntronA 25 million IU/2.5 mL solution for injection or infusion interferon alfa-2b
IntronA 25 milijonov i.e./2,5 ml raztopina za injiciranje ali infundiranje interferon alfa-2b
IntronA 25 MIU solution
IntronA 25 mio i.e. raztopina
IntronA 3 MIU solution
IntronA 3 mio i.e. raztopina
IntronA 3 MIU/m2 3 times a week
IntronA 3 mio i.e./m2 3–krat na teden
IntronA 3 MIU/m2 is administered subcutaneously 3 times a week (every other day) in combination with ribavirin capsules or oral solution administered orally in two divided doses daily with food (morning and evening).
Zdravilo IntronA 3 milijone i.e. /m2 se uporablja subkutano trikrat na teden (vsak drugi dan) v kombinaciji s kapsulami ali peroralno raztopino ribavirina peroralno v dveh deljenih odmerkih s hrano (zjutraj in zvečer).
IntronA 30 million IU solution for injection in multidose pen
IntronA 30 milijonov i.e., raztopina za injiciranje, večodmerni peresnik
IntronA 30 million IU solution for injection in multidose pen interferon alfa-2b
IntronA 30 milijonov i.e. raztopina za injiciranje v večodmernem peresniku interferon alfa-2b
IntronA 30 MIU pen
IntronA 30 mio i.e. peresnik
IntronA 5 million IU/0.5 mL solution for injection or infusion interferon alfa-2b
IntronA 5 milijonov i.e./0,5 ml raztopina za injiciranje ali infundiranje interferon alfa-2b
IntronA 5 MIU solution
IntronA 5 mio i.e. raztopina
IntronA 60 million IU solution for injection in multidose pen
IntronA 60 milijonov i.e., raztopina za injiciranje, večodmerni peresnik
IntronA 60 million IU solution for injection in multidose pen interferon alfa-2b
IntronA 60 milijonov i.e. raztopina za injiciranje v večodmernem peresniku interferon alfa-2b
IntronA 60 MIU pen
IntronA 60 mio i.e. peresnik
IntronA alone
Zdravilo IntronA v monoterapiji
IntronA can be put back in the refrigerator at any time during this seven- day period.
Zdravilo IntronA lahko kadar koli v tem 7 dnevnem obdobju vrnete nazaj v hladilnik.
IntronA can be put back in the refrigerator at any time during this seven-day period.
Zdravilo IntronA lahko postavite nazaj v hladilnik kadar koli v teh 7 dneh.
IntronA can be used in combination with cytarabine (an anticancer medicine) in the first year; multiple myeloma (a cancer of the bone marrow).
Zdravilo IntronA je v prvem letu mogoče uporabljati v kombinaciji s citarabinom (zdravilom proti raku) v prvem letu; multiplega mieloma (raka kostnega mozga).
IntronA contains less than 1 mmol sodium (23 mg) per 1.2 mL, i.e., essentially "sodium-free".
Zdravilo IntronA vsebuje manj kot 1 mmol (23 mg) natrija na 1,2 ml, kar v bistvu pomeni "brez natrija".
IntronA in combination with ribavirin
Zdravilo IntronA v kombinaciji z ribavirinom
IntronA is available in four different pack sizes:
Zdravilo IntronA je na voljo v štirih različnih pakiranjih:
IntronA is available in nine different pack sizes:
Zdravilo IntronA je na voljo v devetih različnih pakiranjih:
IntronA is available in three different pack sizes:
Zdravilo IntronA je na voljo v treh različnih velikostih pakiranja:
IntronA is available in twelve different pack sizes:
Zdravilo IntronA je na voljo v dvanajstih različnih pakiranjih:
IntronA is indicated, in a combination regimen with ribavirin, for the treatment of children 3 years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for HCV-RNA.
Zdravilo IntronA je indicirano v kombinaciji z ribavirinom za zdravljenje otrok, starih 3 leta ali več, in mladostnikov, ki imajo predhodno nezdravljen kronični hepatitis C brez jetrne dekompenzacije in pozitiven izvid HCV-RNA.
IntronA is presented as a solution for injection in a multidose pen.
IntronA je na voljo kot raztopina za injiciranje v večodmernem peresniku.
IntronA is supplied as:
Zdravilo IntronA je na voljo v naslednjih pakiranjih:
IntronA therapy may be initiated if TSH levels can be maintained in the normal range by medication.
Zdravljenje z zdravilom IntronA lahko uvedete, če boste vrednosti TSH lahko z zdravili ohranjali v normalnem razponu.
IntronA treatment may be initiated if TSH levels can be maintained in the normal range by medication.
Terapijo z zdravilom IntronA lahko začnete, če je koncentracijo TSH mogoče z zdravili ohranjati v normalnem razponu vrednosti.
IntronA with food and drink and alcohol
Zdravilo IntronA skupaj s hrano, pijačo in alkoholom
IntronA, solution for injection in multidose pen is injected subcutaneously after attaching an injection needle and dialing the prescribed dose.
IntronA, raztopina za injiciranje v večodmernem peresniku, se injicira subkutano po namestitvi injekcijske igle in nastavitvi predpisanega odmerka.
Intuniv 1 mg prolonged-release tablets Guanfacine
Intuniv 1 mg tablete s podaljšanim sproščanjem gvanfacin
Intuniv 1mg prolonged-release tablets Intuniv 2mg prolonged-release tablets Intuniv 3mg prolonged-release tablets Intuniv 4mg prolonged-release tablets Guanfacine
Intuniv 1 mg tablete s podaljšanim sproščanjem Intuniv 2 mg tablete s podaljšanim sproščanjem Intuniv 3 mg tablete s podaljšanim sproščanjem Intuniv 4 mg tablete s podaljšanim sproščanjem gvanfacin
Intuniv has not been studied in adults with ADHD.
Zdravila Intuniv pri odraslih z ADHD niso proučevali.
intussusception (a bowel obstruction in which one segment of bowel becomes enfolded within another segment)*, †.
invaginacija (zaprtje črevesja, pri čemer se en del črevesja uviha v drugi del črevesja)*,
Intussusception (see section 4.4)
invaginacija (glejte poglavje 4.4)
Intussusception α *
Invaginacija α
inus arrhythmia
blok, podaljšan
inus arrhythmia, electrocardiogram abnormal, palpitations
inusna aritmija, nenormalen elektrokardiogram, palpitacije
inus congestion
zamašeni sinusi
inus congestion*
kongestija obnosnih votlin*,
inus infection
okužba sinusov
inus infection
vnetje sinusa,
inus pain
bolečine v sinusih
inusitis
inuzitis
inusitis
Sinuzitis
inusitis (inflammation of nasal sinus)
inusitis (vnetje nosnih sinusov)
inusitis, cough increased, shortness of breath (dyspnoea)
kratka sapa (dispneja)
inusitis, respiratory infections, stuffy or runny nose, difficulty in speaking, nosebleed, cold sores (herpes simplex), fungal or bacterial infections, ear infection/earache,
inusitis, okužbe dihal, zamašen nos ali izcedek iz nosu, težave z govorom, krvavitev iz nosu, herpes (herpes simplex), glivne ali bakterijske okužbe, okužbe ušes/bolečine v ušesih,
INVANZ 1 g powder for concentrate for solution for infusion ertapenem
INVANZ 1 g prašek za koncentrat za raztopino za infundiranje ertapenem
Invanz also has an effect on some blood tests.
Zdravilo Invanz vpliva tudi na nekatere krvne preiskave.
Invanz is a medicine that contains the active substance ertapenem.
Invanz je zdravilo, ki vsebuje zdravilno učinkovino ertapenem.
INVANZ is a white to off-white, freeze-dried powder for concentrate for solution for infusion.
Zdravilo INVANZ je bel do sivobel, liofiliziran prašek za koncentrat za raztopino za infundiranje.